Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder
2021-000133-13Phase 2Active
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in binge eating disorder (BED) comparing Hydrocortisone + ERP with Placebo + ERP (2 arms). Primary endpoint: Decrease of food craving in response to real food 3–5 days after treatment. Started Jan 2022; status: active.
02
Drugs
hydrocortisone
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on 2021-000133-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000133-13.